Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:CGEN

Compugen Q3 2026 Earnings Date & Estimates

Compugen logo
$2.00 +0.02 (+1.01%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$2.04 +0.04 (+1.75%)
As of 08:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compugen is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Compugen in Q3 2026

Compugen is expected to post earnings of -$0.08 per share on revenue of $1.29 million. In the same quarter a year earlier Compugen reported -$0.07 per share on revenue of $1.89 million. Compugen last reported on August 3, 2026, posting -$0.07 per share and beating the -$0.08 consensus estimate. Compugen has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.08
Expected Revenue
$1.29 million
Prior-Year EPS
-$0.07
Prior-Year Revenue
$1.89 million
Expected Revenue Growth
-32.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Beat by +$0.01)
Last Quarter Revenue
$2.60 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Compugen Q3 2026 Earnings FAQ

Compugen (NASDAQ:CGEN) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Compugen's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Compugen to post earnings of -$0.08 per share for Q3 2026.

The consensus revenue estimate for Compugen is $1.29 million for Q3 2026.

Compugen Earnings Headlines

Compugen (NASDAQ:CGEN) Given "Buy" Rating at HC Wainwright
October 12 at 8:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110320
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Compugen (CGEN)
October 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/5006107/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-and-compugen-cgen/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 15 at 1:00 AM  |  Chaikin Analytics (Ad)
Stifel Nicolaus Remains a Buy on Compugen (CGEN)
October 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CGEN-Q/pressreleases/5002298/stifel-nicolaus-remains-a-buy-on-compugen-cgen/
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
October 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/compugen-to-participate-in-a-fireside-chat-at-the-hc-wainwright-3rd-annual-ai-based-drug-discovery--development-conference-302899511.html
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951991-compugen-ltd-cgen-discusses-com701-in-ovarian-cancer-maia-trial-preview-and-unigen-platform
See More Compugen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Compugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compugen and other key companies, straight to your email.

About Compugen

Compugen (NASDAQ:CGEN) (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT. These programs have been evaluated as potential treatments for solid tumors, including in combination with other cancer therapies. The company’s research has also focused on discovering previously unrecognized immune-regulatory mechanisms and developing proprietary therapeutic candidates around those findings.

Founded in 1993, Compugen is headquartered in Holon, Israel, and its shares are listed on the Nasdaq Capital Market under the symbol CGEN. The company has pursued research and development collaborations with pharmaceutical and biotechnology partners to advance selected programs. Compugen has been led by President and Chief Executive Officer Anat Cohen-Dayag, who has been associated with the company’s management and strategic development for many years.

View Compugen Profile
Earnings Tools